A Novel Genetic TDP-43 Pig Model Mimics Multiple Key ALS-Like Features

Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that lacks ideal models to comprehensively recapitulate its pathological features. TDP-43 pathology, a hallmark of neurodegenerative diseases, plays a critical role in disease progression. Given the anatomical and physiological similarities between pig and human brains, large animal models offer a unique advantage in more accurately simulating patient-specific disease characteristics. In this study, we rapidly established a TDP-43-induced neurodegenerative disease model in pigs through ear vein injection of the TDP-43^M337V virus. Disease progression was systematically evaluated using behavioral assessments and pathological analyses. This porcine model produced extremely severe motor dysfunction accompanied by significant muscle atrophy and fibrosis. Additionally, characteristic TDP-43 pathological phenotypes were observed, including degeneration of spinal motor neurons and proliferation of glial cells in both the brain and spinal cord. Notably, TDP-43^M337V induction led to a significant upregulation of TMEM106B, SOD1, and APOE4 levels. This TDP-43 porcine model recapitulates multiple key features of ALS and serves as a valuable complement to existing animal models, providing a robust platform for investigating TDP-43-related pathogenic mechanisms of TDP-43 and developing effective therapeutics.

Keywords

amyotrophic lateral sclerosis / APOE4 / movement disorder / pig model / SOD1 / TDP-43

References

[1] R. H. Brown and A. Al-Chalabi, “Amyotrophic Lateral Sclerosis,” New England Journal of Medicine 377, no. 2 (2017): 162-172.

[2] L. Xu, T. Liu, L. Liu, et al., “Global Variation in Prevalence and Incidence of Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis,” Journal of Neurology 267, no. 4 (2020): 944-953.

[3] R. Chia, A. Chio, and B. J. Traynor, “Novel Genes Associated With Amyotrophic Lateral Sclerosis: Diagnostic and Clinical Implications,” Lancet Neurology 17, no. 1 (2018): 94-102.

[4] S. Lepine, M. J. Castellanos-Montiel, and T. M. Durcan, “TDP-43 Dysregulation and Neuromuscular Junction Disruption in Amyotrophic Lateral Sclerosis,” Translational Neurodegeneration 11, no. 1 (2022): 56.

[5] D. R. Rosen, T. Siddique, and D. Patterson, “Mutations in Cu/Zn Superoxide Dismutase Gene Are Associated With Familial Amyotrophic Lateral Sclerosis,” Nature 362, no. 6415 (1993): 59-62.

[6] P. M. Andersen, “Amyotrophic Lateral Sclerosis Associated With Mutations in the CuZn Superoxide Dismutase Gene,” Current Neurology and Neuroscience Reports 6, no. 1 (2006): 37-46.

[7] M. Neumann, D. M. Sampathu, L. K. Kwong, et al., “Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis,” Science 314, no. 5796 (2006): 130-133.

[8] T. Arai, M. Hasegawa, H. Akiyama, et al., “TDP-43 Is a Component of Ubiquitin-Positive Tau-Negative Inclusions in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis,” Biochemical and Biophysical Research Communications 351, no. 3 (2006): 602-611.

[9] P. Tziortzouda, L. Van Den Bosch, and F. Hirth, “Triad of TDP43 Control in Neurodegeneration: Autoregulation, Localization and Aggregation,” Nature Reviews Neuroscience 22, no. 4 (2021): 197-208.

[10] P. Yin, X. Guo, W. Yang, et al., “Caspase-4 Mediates Cytoplasmic Accumulation of TDP-43 in the Primate Brains,” Acta Neuropathologica 137, no. 6 (2019): 919-937.

[11] A. Uchida, H. Sasaguri, N. Kimura, et al., “Non-Human Primate Model of Amyotrophic Lateral Sclerosis With Cytoplasmic Mislocalization of TDP-43,” Brain 135, no. 3 (2012): 833-846.

[12] P. Yin, S. Li, X. J. Li, and W. Yang, “New Pathogenic Insights From Large Animal Models of Neurodegenerative Diseases,” Protein Cell 13, no. 10 (2022): 707-720.

[13] J. K. Lunney, A. Van Goor, K. E. Walker, et al., “Importance of the Pig as a Human Biomedical Model,” Science Translational Medicine 13, no. 621 (2021): eabd5758.

[14] Y. Lin, C. Li, W. Wang, et al., “Intravenous AAV9 Administration Results in Safe and Widespread Distribution of Transgene in the Brain of Mini-Pig,” Frontiers in Cell and Developmental Biology 10 (2022): 1115348.

[15] A. S. Chen-Plotkin, V. M. Lee, and J. Q. Trojanowski, “TAR DNA-Binding Protein 43 in Neurodegenerative Disease,” Nature Reviews Neurology 6, no. 4 (2010): 211-220.

[16] M. Neumann, P. Frick, F. Paron, et al., “Antibody Against TDP-43 Phosphorylated at Serine 375 Suggests Conformational Differences of TDP-43 Aggregates Among FTLD-TDP Subtypes,” Acta Neuropathologica 140, no. 5 (2020): 645-658.

[17] M. D. Cykowski, S. Z. Powell, J. W. Appel, et al., “Phosphorylated TDP-43 (pTDP-43) Aggregates in the Axial Skeletal Muscle of Patients With Sporadic and Familial Amyotrophic Lateral Sclerosis,” Acta Neuropathologica Communications 6, no. 1 (2018): 28.

[18] Q. J. Zhang, J. Lin, Y. L. Wang, et al., “Detection of pTDP-43 via Routine Muscle Biopsy: A Promising Diagnostic Biomarker for Amyotrophic Lateral Sclerosis,” Brain Pathology 34, no. 6 (2024): e13261.

[19] T. Feng, A. Lacrampe, and F. Hu, “Physiological and Pathological Functions of TMEM106B: A Gene Associated With Brain Aging and Multiple Brain Disorders,” Acta Neuropathologica 141, no. 3 (2021): 327-339.

[20] F. Mao, J. L. Robinson, T. Unger, et al., “TMEM106B Modifies TDP-43 Pathology in Human ALS Brain and Cell-Based Models of TDP-43 Proteinopathy,” Acta Neuropathologica 142, no. 4 (2021): 629-642.

[21] A. E. Arrant, A. M. Nicholson, X. Zhou, R. Rademakers, and E. D. Roberson, “Partial Tmem106b Reduction Does Not Correct Abnormalities due to Progranulin Haploinsufficiency,” Molecular Neurodegeneration 13, no. 1 (2018): 32.

[22] X. Zhou, L. Sun, O. A. Brady, K. A. Murphy, and F. Hu, “Elevated TMEM106B Levels Exaggerate Lipofuscin Accumulation and Lysosomal Dysfunction in Aged Mice With Progranulin Deficiency,” Acta Neuropathologica Communications 5, no. 1 (2017): 9.

[23] J. K. Götzl, K. Mori, M. Damme, et al., “Common Pathobiochemical Hallmarks of Progranulin-Associated Frontotemporal Lobar Degeneration and Neuronal Ceroid Lipofuscinosis,” Acta Neuropathologica 127, no. 6 (2014): 845-860.

[24] Z. A. Klein, H. Takahashi, M. Ma, et al., “Loss of TMEM106B Ameliorates Lysosomal and Frontotemporal Dementia-Related Phenotypes in Progranulin-Deficient Mice,” Neuron 95, no. 2 (2017): 281-296.e286.

[25] B. G. Trist, J. A. Fifita, A. Hogan, et al., “Co-Deposition of SOD1, TDP-43 and p62 Proteinopathies in ALS: Evidence for Multifaceted Pathways Underlying Neurodegeneration,” Acta Neuropathologica Communications 10, no. 1 (2022): 122.

[26] N. Zhao, C.-C. Liu, W. Qiao, and G. Bu, “Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease,” Biological Psychiatry 83, no. 4 (2018): 347-357.

[27] K. A. Josephs, J. L. Whitwell, S. D. Weigand, et al., “TDP-43 Is a Key Player in the Clinical Features Associated With Alzheimer's Disease,” Acta Neuropathologica 127, no. 6 (2014): 811-824.

[28] H.-S. Yang, L. Yu, C. C. White, et al., “Evaluation of TDP-43 Proteinopathy and Hippocampal Sclerosis in Relation to APOE ε4 Haplotype Status: A Community-Based Cohort Study,” The Lancet Neurology 17, no. 9 (2018): 773-781.

[29] A. Chiot, S. Zaidi, C. Iltis, et al., “Modifying Macrophages at the Periphery Has the Capacity to Change Microglial Reactivity and to Extend ALS Survival,” Nature Neuroscience 23, no. 11 (2020): 1339-1351.

[30] F. Dangond, D. Hwang, S. Camelo, et al., “Molecular Signature of Late-Stage Human ALS Revealed by Expression Profiling of Postmortem Spinal Cord Gray Matter,” Physiological Genomics 16, no. 2 (2004): 229-239.

[31] O. H. Tam, N. V. Rozhkov, R. Shaw, et al., “Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia,” Cell Reports 29, no. 5 (2019): 1164-1177.e1165.

[32] K. Fujimori, M. Ishikawa, A. Otomo, et al., “Modeling Sporadic ALS in iPSC-Derived Motor Neurons Identifies a Potential Therapeutic Agent,” Nature Medicine 24, no. 10 (2018): 1579-1589.

[33] P. Sauleau, E. Lapouble, D. Val-Laillet, and C. H. Malbert, “The Pig Model in Brain Imaging and Neurosurgery,” Animal 3, no. 8 (2009): 1138-1151.

[34] P. Yin, D. Bai, F. Deng, et al., “SQSTM1-Mediated Clearance of Cytoplasmic Mutant TARDBP/TDP-43 in the Monkey Brain,” Autophagy 18, no. 8 (2021): 1955-1968.

[35] G. Wang, H. Yang, S. Yan, et al., “Cytoplasmic Mislocalization of RNA Splicing Factors and Aberrant Neuronal Gene Splicing in TDP-43 Transgenic Pig Brain,” Molecular Neurodegeneration 10 (2015): 42.

[36] P. Crociara, M. N. Chieppa, E. Vallino Costassa, et al., “Motor Neuron Degeneration, Severe Myopathy and TDP-43 Increase in a Transgenic Pig Model of SOD1-Linked Familiar ALS,” Neurobiology of Disease 124 (2019): 263-275.

[37] H. Yang, G. Wang, H. Sun, et al., “Species-Dependent Neuropathology in Transgenic SOD1 Pigs,” Cell Research 24, no. 4 (2014): 464-481.

[38] R. J. Mead, N. Shan, H. J. Reiser, F. Marshall, and P. J. Shaw, “Amyotrophic Lateral Sclerosis: A Neurodegenerative Disorder Poised for Successful Therapeutic Translation,” Nature Reviews Drug Discovery 22, no. 3 (2023): 185-212.

[39] L. I. Grad, G. A. Rouleau, J. Ravits, and N. R. Cashman, “Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS),” Cold Spring Harbor Perspectives in Medicine 7, no. 8 (2017): a024117.

[40] S. Yan, Z. Tu, Z. Liu, et al., “A Huntingtin Knockin Pig Model Recapitulates Features of Selective Neurodegeneration in Huntington's Disease,” Cell 173, no. 4 (2018): 989-1002 e1013.

[41] S. Yan, X. Zheng, Y. Lin, et al., “Cas9-Mediated Replacement of Expanded CAG Repeats in a Pig Model of Huntington's Disease,” Nature Biomedical Engineering 7, no. 5 (2023): 629-646.

[42] H. Mitsumoto, B. R. Brooks, and V. Silani, “Clinical Trials in Amyotrophic Lateral Sclerosis: Why so Many Negative Trials and How Can Trials be Improved?,” Lancet Neurology 13, no. 11 (2014): 1127-1138.

[43] C. Perleberg, A. Kind, and A. Schnieke, “Genetically Engineered Pigs as Models for Human Disease,” Disease Models & Mechanisms 11, no. 1 (2018): dmm030783.

[44] Y. Lu, J. Ferris, and F. B. Gao, “Frontotemporal Dementia and Amyotrophic Lateral Sclerosis-Associated Disease Protein TDP-43 Promotes Dendritic Branching,” Molecular Brain 2 (2009): 30.

[45] A. M. Bolger, M. Lohse, and B. Usadel, “Trimmomatic: A Flexible Trimmer for Illumina Sequence Data,” Bioinformatics 30, no. 15 (2014): 2114-2120.

[46] K. L. Howe, P. Achuthan, J. Allen, et al., “Ensembl 2021,” Nucleic Acids Research 49, no. D1 (2021): D884-D891.

[47] H. Li, B. Handsaker, A. Wysoker, et al., “The Sequence Alignment/Map Format and SAMtools,” Bioinformatics 25, no. 16 (2009): 2078-2079.

[48] M. Pertea, G. M. Pertea, C. M. Antonescu, et al., “StringTie Enables Improved Reconstruction of a Transcriptome From RNA-seq Reads,” Nature Biotechnology 33, no. 3 (2015): 290-295.

[49] M. I. Love, W. Huber, and S. Anders, “Moderated Estimation of Fold Change and Dispersion for RNA-seq Data With DESeq2,” Genome Biology 15, no. 12 (2014): 550.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.